The CBHSQ Report header
Center for Behavioral Health Statistics and Quality
Short Report
November 04, 2015*
Image of doctor writing of clipboard
In Brief
  • About 3.4 million visits to physician offices in 2010 involved medication prescriptions to treat substance use disorders (SUD).
     
  • About 44.3 percent of the prescriptions for AUD and OUD were made in these office visits by general and family practice physicians, and 20.1 percent were made by psychiatrists.
     
  • Regardless of specialty, behavioral treatment for these substance use disorders (SUDs) was only provided in a minority of office visits (34.3 percent) during which SUD medications were prescribed.
Medication Prescribing and Behavioral Treatment for Substance Use Disorders in Physician Office Settings
Authors

Margaret E. Mattson, Ph.D., and Sean Lynch, Ph.D., L.C.S.W.

Introduction

More than 17 million persons aged 12 or older in the United States in 2013 (6.6 percent of the population) had alcohol use disorders (AUD), and about 2.4 million had opioid use disorders (OUD).1 The current medications approved by the Food and Drug Administration (FDA) for the treatment of OUD are methadone, buprenorphine (Subutex®), buprenorphine/naloxone (Suboxone®), and oral as well as injectable naltrexone (Vivitrol®).2 Some of these medications require physicians to apply for a waiver from the Drug Enforcement Agency in order to prescribe them outside of a narcotic treatment program (i.e., clinic). The medications approved for AUD are naltrexone oral (ReVia®, Depade®), naltrexone injectable (Vivitrol®), disulfiram (Antabuse®), acamprosate (Campral®).3  Collectively these medications are referred to as substance use disorders (SUDs) medications in this report.

It has been reported that maintenance medication is underutilized in treatment for substance use disorders.4 Although a combination of medication and behavioral treatment is recommended to treat these chronic disorders, medication and behavioral treatments such as counseling have traditionally been carried out in separate settings. Treatment for substance abuse has been provided in specialized facilities separate from mainstream medical practices. These specialized facilities tended to provide mostly behavioral treatment, with a smaller proportion providing medication treatment. This separation of the two forms of treatment has not provided optimal care for patients with substance use disorders (SUD).4 Only recently have office-based practices begun to incorporate screening and referral services, and to a more limited degree medication.5

Little is known about the degree to which SUD medication is prescribed by office-based physicians, the specialty of those who do prescribe, and the associated diagnoses. Likewise, information is scarce about the extent to which combined care involving medication and behavioral treatment for common types of SUD treatment is occurring. This report addresses these questions using data from the 2010 National Ambulatory Medical Care Survey (NAMCS), an annual survey from a sample of physicians who deliver care directly to patients in their offices.6

Prescriptions for Alcohol and Opioid Use Disorders and Specialty of the Provider

Slightly more than 1 trillion visits were made in 2010 to physicians’ offices, for a rate of 332.3 visits per 100 persons in the United States. Of these visits, about 757 million visits (about three-quarters of the total) involved prescribing new or continuing medications, with 0.5 percent (3.4 million) of these visits involving prescriptions for medications to treat SUD. With regard to the specialty of the prescribing physician, 44.3 percent of the prescriptions for SUD were given by general and family practice physicians, 20.1 percent were given by psychiatrists, and the remaining 35.6 percent were given by all other specialties combined (Figure 1). Approximately 32.5 percent of the prescriptions for SUD were written by the patient’s primary care provider.

Figure 1. Substance use disorder (SUD) prescriptions provided by office-based physicians, by medical specialty: 2010

This pie chart shows substance use disorder prescriptions provided by office-base physicians in 2010, by medical specialty. In 2010, 37.3% of substance use disorder prescriptions were provided by general and family practice physicians, 17.5% were provided by psychiatrists, 11.3% were provided by internists, 8.2% were provided by neurologists, and 25.8% were provided by physicians with other specialties.

This report examines whether the prescriptions given for the 3.4 million SUD-related visits were connected with an appropriate diagnosis requiring the prescriptions. Physicians who prescribe a medication to treat SUD would typically diagnose substance disorder (either AUD or OUD) for that visit. Of the medications prescribed for SUD, only 34.3 percent were associated with a substance use disorder diagnosis (Figure 2). 

Figure 2. Percentage and number of substance use disorder prescriptions provided by office-based physicians, by diagnosis: 2010

This pie chart shows the number and percent of opioid use disorder prescriptions provided by office-based physicians in 2010, by diagnosis. In 2010, 3,032,669 prescriptions for medications used to treat opioid use disorder (27.7%) were related to opioid use disorder, and 7,898,833 prescriptions for such medications (72.3%) were not related to opioid use disorder.

     

The proportion of office visits for substance abuse medications during which some form of behavioral treatment was also provided was examined in the 2010 NAMCS. The survey assessed provision of or referral to psychotherapy or other mental health counseling, as well as whether a mental health provider provided care. For all substance abuse medication visits, 34.3 percent of the visits also involved some form of behavioral treatment; approximately 27.1 percent of these included both receipt of psychotherapy and other mental health counseling. 

DISCUSSION

In this study general and family practice physicians were found to prescribe 44.3 percent of medications to treat SUD prescribed in physician office settings. The bulk of the prescribing of these medications is done by other medical specialties. Although this result suggests that these treatments are available in some office settings, we might have expected even greater accessibility to SUD medications in physician office settings. One barrier is that nationwide just 3% of primary care physicians have the required DEA waiver.7  A third of the physicians in this study who prescribed medications for SUD were also the patient’s primary care physician. While the efficacy of medications to treat SUD has been established, general and family practice physicians may be unfamiliar with these drugs, lack clear clinical guidelines for their use,8 and/or may refer to self-help approaches. State-specific accrediting agencies with their own regulations and guidelines for medication-assisted treatment of OUD may also be restrictive.  Continued education on clinical guidelines may promote increased prescribing of SUD medications along with integration of behavioral treatment.9

Several factors may explain why physicians who are prescribing SUD medications are not recording an SUD diagnosis. First, physicians may not always assign a diagnosis such as opioid dependence or alcohol abuse/dependence because of concerns related to patient resistance or denial of the condition, or potential workplace discrimination.10,11 Second, some of these medications can be prescribed for conditions other than SUD. Finally, some physicians may not record diagnoses that were not connected to the primary reason for the visits, although they may still continue the SUD medication treatment prescribed previously.

Best practices for opiate and alcohol use disorders hold that along with medication, some form of behavioral treatment should be given, such as direct physician advice and counseling, and more involved interventions such as contingency management, community reinforcement approach plus vouchers, and 12-Step Facilitation therapy.12 This report finds that only a minority of office visits for medications to treat SUD include provision of or referral to behavioral treatment. Although psychiatrists may be able to provide psychotherapy during a visit, other physician specialties may be unequipped to provide or even refer to behaviorally oriented services due to lack of training, experience or resources. Consequently, patients may not be receiving an optimal mix of both medication and behavioral treatment to address their substance abuse. 

These results suggest that continued work is necessary to achieve further incorporation of behavioral and medical treatment of SUD into office-based care.  Research on the barriers and facilitators of integration will help to us to understand the possible benefits of bringing substance abuse treatment into a more accessible setting.13 Bringing medical and behavioral treatment together in physician offices can increase the accessibility and effectiveness of substance abuse treatment, as well as reduce health care costs associated with substance abuse.14,15,16 

Guidance for medication assisted therapy protocols is provided in several documents available through http://www.samhsa.gov.

End Notes
  1. Center for Behavioral Health Statistics and Quality. (2014, September 4). Table 5.14A—Substance dependence for specific substances in the past year, by age group: Numbers in thousands, 2012 and 2013. Retrieved from http://www.samhsa.gov/data/sites/default/files/NSDUH-DetTabsPDFWHTML2013/Web/HTML/NSDUH-DetTabsSect5peTabs1to56-2013.htm#tab5.14a
  2. Center for Substance Abuse Treatment. (2005). Medication-assisted treatment for opioid addiction in opioid treatment programs (Treatment Improvement Protocol [TIP] 43). Rockville, MD: Substance Abuse and Mental Health Services Administration.
  3. National Institute on Alcoholism and Alcohol Abuse. (2005). Helping patients who drink too much: A clinician’s guide. Updated 2005 edition. Retrieved from http://pubs.niaaa.nih.gov/publications/Practitioner/CliniciansGuide2005/clinicians_guide.htm
  4. McLellan, A. T., & Woodworth, A. M. (2014). The Affordable Care Act and treatment for "substance use disorders": Implications of ending segregated behavioral healthcare. Journal of Substance Abuse Treatment, 46(5), 541–545. doi:10.1016/j.jsat.2014.02.001
  5. Center for Integrated Studies. (2013, May). Innovations in addiction treatment: Addiction treatment providers working with integrated primary care services. Retrieved from http://www.integration.samhsa.gov/clinical-practice/13_May_CIHS_Innovations.pdf
  6. National Center for Health Statistics. (2014). National Ambulatory Medical Care Survey. Retrieved from http://www.cdc.gov/nchs/ahcd.htm
  7. Rosenblatt, R. A., Andrilla, C. H., Catlin, M., Larson, E. H. (2015). Geographic and specialty distribution of US physicians trained to treat opioid disorder.  Annals of Family Medicine, 13(1), 23-6. doi:10.1370/afm.1735 
  8. Kranzler, H. R., & Van Kirk, J. (2001). Efficacy of naltrexone and acamprosate for alcoholism treatment: A meta-analysis. Alcoholism: Clinical and Experimental Research, 25(9), 1335–1341.
  9. Substance Abuse and Mental Health Services Administration and National Institute on Alcohol Abuse and Alcoholism. (2015). Medication for the treatment of alcohol use disorder: A brief guide (HHS Publication No. SMA 15–4907). Rockville, MD: Substance Abuse and Mental Health Services Administration and National Institute on Alcohol Abuse and Alcoholism.
  10. Link, B. G. (1987). Understanding labeling effects in the area of mental disorders: An assessment of the effects of expectations of rejection. American Sociological Review, 52(1), 96–112.
  11. Jorm, A. F. (2000). Mental health literacy. British Journal of Psychiatry, 177(5), 396–401.
  12. National Institute of Drug Abuse. (2014). Principles of drug addiction treatment: A research-based guide (3rd ed.). Retrieved from http://www.drugabuse.gov/publications/principles-drug-addiction-treatment/evidence-based-approaches-to-drug-addiction-treatment/behavioral-therapies
  13. Roman, P. M., Abraham, A. J., & Knudson, H. K. (2011). Using medication-assisted treatment for substance use disorders: Evidence of barriers and facilitators of implementation. Addictive Behaviors, 36(6), 584–589.
  14. Gastfriend, D. R. (2014). A pharmaceutical industry perspective on the economics of treatments for alcohol and opioid use disorders. Annals of the New York Academy of Science, 1327, 112–130. doi:10.1111/nyas.12538
  15. Mark, T. L., Montejano, L. B., Kranzler, H. R., Chalk, M., & Gastfriend, D. R. (2010). Comparison of healthcare utilization among patients treated with alcoholism medications. American Journal of Managed Care, 16(12), 879–888.
  16. Oslin, D., Lynch,K.G., Maisto, S.S., Lantinga, L.J., Mckay, J.R., Passemato, K., Ingram, B.A., & Wierzbick, M. (2014). Clinical trial of alcohol care management delivered in Department of Veterans Affairs primary care clinics vs. specialty treatment.  Journal of General Internal Medicine, 29(1), 162-168. 
Suggested Citation

Margaret E. Mattson, Ph.D. and Sean Lynch, Ph.D., L.C.S.W. The CBHSQ Report: Medication Prescribing and Behavioral Treatment for Substance Use Disorders in Physician Office Settings. Substance Abuse and Mental Health Services Administration, Center for Behavioral Health Statistics and Quality. Rockville, MD.